Quoin gets FDA Fast Track for QRX003 in peeling skin syndrome
The designation, Quoin's second for the topical drug, follows July 2026 clearance of the first-ever IND filed for the rare skin disease.
SEC filing
Latest
6 stories
Tuesday, September 22
Thursday, September 10
Quoin Pharmaceuticals reports $50 million private placement in Form D filing
The Israel-incorporated pharmaceutical company sold securities to 33 investors with a first sale date of August 31, 2026, according to its SEC filing.
SEC filing
FDA grants second Rare Pediatric Disease designation to Quoin's QRX003
The designation covers Peeling Skin Syndrome, following an earlier RPD designation for Netherton Syndrome, and could make Quoin eligible for a priority review voucher.
SEC filing
Friday, August 28
Quoin prices $50 million private placement, reports positive Netherton Syndrome data
Quoin Pharmaceuticals paired its financing with interim Phase 2/3 results showing QRX003 met its primary endpoint in six patients.
SEC filing
Thursday, August 20
Quoin Pharmaceuticals shareholders vote on five proposals at 2026 annual meeting
Investors elected seven directors, approved executive pay on an advisory basis, and raised director compensation limits at the August 20, 2026 meeting.
SEC filing
Friday, August 14
Quoin reports Q2 2026 results, FDA clearance for peeling skin syndrome IND
Quoin Pharmaceuticals said the FDA cleared its IND for Peeling Skin Syndrome after quarter end, setting up a Phase 2/3 study to start in the second half of 2026.
SEC filing